

590 | 51

Views | CrossRef citations to date | 6 | Altmetric

Original Articles: Clinical

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

Sucha Nand , John Godwin, Scott Smith, Kevin Barton, Laura Michaelis, Serhan Alkan, ... show all

Pages 2141-2147 | Received 16 Jun 2008, Accepted 27 Aug 2008, Published online: 01 Jul 2009

Cite this article <https://doi.org/10.1080/10428190802451254>

We Care About Your Privacy

We and our 880 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

I Accept

Reject All

Show Purpose



Full Ar

Repri

Abstr

Elderly

syndrom

standar

study, w

gemtuzu

patients

The trea

plastic

(6) to

this Phase II

e

up of

regimen.

the blood cell

count below 10,000/ μL , followed by azacitidine 75 mg/ m^2 subcutaneously for 7 days and GO 3 mg/ m^2 on day 8. Patients who achieved complete remission (CR) received a consolidation course. The median age of patients was 76 years. Eleven patients (55%) were treated in the outpatient setting. Fourteen (70%) achieved a CR, three of which were incomplete (CRi). The median duration of remission was 8 months and median survival was 10 months. Performance status of 0–1 was associated with high complete response rate. Overall toxicity was acceptable with only one (5%) early death due to disease progression. The combination of HU, azacitidine and GO appears to be a safe and effective regimen in the treatment of AML and high risk MDS in the elderly. These results need to be confirmed in a larger cohort of patients.

Keywords: [Acute myeloid leukemia](#) [azacitidine](#) [gemtuzumab ozogamicin](#)

Related research

People also read

Recommended articles

Cited by
51



Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright

Accessib

Registered
5 Howick Pl

or & Francis Group
orma business

